[go: up one dir, main page]

AR078201A1 - Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos - Google Patents

Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Info

Publication number
AR078201A1
AR078201A1 ARP100103564A ARP100103564A AR078201A1 AR 078201 A1 AR078201 A1 AR 078201A1 AR P100103564 A ARP100103564 A AR P100103564A AR P100103564 A ARP100103564 A AR P100103564A AR 078201 A1 AR078201 A1 AR 078201A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluoro
group
ring
substituted
Prior art date
Application number
ARP100103564A
Other languages
English (en)
Inventor
Andiappan Murugan
Mark Ashton
Martin Lindsjoe
Peter Olof Sjoe
John Meigh
Lena Kristina Bergstrom
Anna Kristoffersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR078201A1 publication Critical patent/AR078201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Procesos e intermediarios para prepararlos, composiciones farmacéuticas que los contienen y su uso en terapia. Los compuestos son inhibidores de la elastasa de neutrofilos humanos. Reivindicacion 1. Un compuesto caracterizado porque tiene la formula (1) donde R1 representa hidrogeno o alquilo C1-4; R7 representa un anillo de fenilo o piridinilo, donde dicho anillo está 4- (para) sustituido con fluoro, cloro o CN; X representa N o CR2, donde R2 representa H o fluoro; R3 representa un grupo fenilo sustituido con uno o dos sustituyentes seleccionados de manera independiente entre fluor, cloro y trifluorometilo; L representa alquileno C2-4; R4, R5 y R6 representan independientemente alquilo C1-6; o R4 y R5 pueden estar unidos de manera que el grupo NR4R5 representa un grupo cíclico amonio de 5 o 6 miembros; y Y representa un anion farmacéuticamente aceptable. Reivindicacion 18: Un compuesto caracterizado porque es de la formula (2) donde R1 representa hidrogeno o alquilo C1-4; R7 representa un anillo de fenilo o piridinilo; donde dicho anillo está 4- (para) sustituido con fluoro, cloro o CN; X representa N o CR2, donde R2 representa H o fluoro; R3 representa un grupo fenilo sustituido con uno o dos sustituyentes seleccionados de manera independiente entre fluor, cloro y trifluorometilo; L representa alquileno C2-4; R4 y R5 representan independientemente alquilo C1-6; o R4 y R5 pueden estar unidos de manera que el grupo NR4R5 representa un grupo cíclico de 5 o 6 miembros; o una sal de éste. Reivindicacion 19: Un compuesto caracterizado porque es de la formula (8), o una sal de éste donde R1' representa alquilo C1-4; X representa N o CR2, donde R2 representa H o fluoro; L representa alquileno C2-4; R4' y R5' representan independientemente alquilo C1-6; o R4' y R5' pueden estar unidos de manera que el grupo NR4'R5' representa un anillo heterocíclico no aromático saturado o parcialmente saturado de 5 o 6 miembros que contiene 1 nitrogeno y opcionalmente 1, 2 o 3 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno; y R9 es halo; o una sal de éste.
ARP100103564A 2009-10-02 2010-09-30 Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos AR078201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24808109P 2009-10-02 2009-10-02

Publications (1)

Publication Number Publication Date
AR078201A1 true AR078201A1 (es) 2011-10-19

Family

ID=42983551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103564A AR078201A1 (es) 2009-10-02 2010-09-30 Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos

Country Status (14)

Country Link
US (1) US8436024B2 (es)
EP (1) EP2483244A1 (es)
JP (1) JP2013506649A (es)
KR (1) KR20120099639A (es)
CN (1) CN102639505A (es)
AR (1) AR078201A1 (es)
AU (1) AU2010302420B2 (es)
BR (1) BR112012007322A2 (es)
CA (1) CA2773618A1 (es)
MX (1) MX2012003644A (es)
RU (1) RU2012116877A (es)
TW (1) TW201118078A (es)
UY (1) UY32918A (es)
WO (1) WO2011039528A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
KR20150031318A (ko) * 2012-07-12 2015-03-23 키에시 파르마슈티시 엣스. 피. 에이. 효소의 억제
AU2013295800A1 (en) * 2012-07-24 2015-03-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2014144572A2 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Substrate profiling of proteases in neutrophil extracellular traps
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
PE20190176A1 (es) * 2016-05-31 2019-02-01 Chiesi Farm Spa Compuestos de imidazolona como inhibidores de la elastasa de neutrofilos humana
KR20200020210A (ko) 2018-08-16 2020-02-26 서울대학교산학협력단 식물 추출물을 함유하는 호중구 엘라스타아제 억제용 조성물
CN114761015A (zh) * 2019-08-23 2022-07-15 Ph制药有限公司 中性粒细胞弹性蛋白酶抑制剂在肺病中的用途
BR112022004861A2 (pt) 2019-09-17 2022-06-07 Univ Duke Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
WO2021195475A1 (en) * 2020-03-27 2021-09-30 Aclaris Therapeutics, Inc. Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
US20230190723A1 (en) 2020-04-16 2023-06-22 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2022165031A1 (en) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Ulinastatin polypeptides for treating diseases
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP2002514196A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジノンおよびピリドン化合物ならびに使用方法
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH1171351A (ja) 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CA2433158C (en) 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
BR0211900A (pt) 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
ATE447971T1 (de) 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003293356A1 (en) 2002-08-27 2004-03-19 Bayer Healthcare Ag Dihydropyridinone derivatives as hne inhibitors
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US8097629B2 (en) 2004-02-19 2012-01-17 Bayer Pharma Aktiengesellschaft Dihydropyridinone derivatives
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
JP4927544B2 (ja) 2004-07-13 2012-05-09 リンテック株式会社 離型シート及びその離型シートを用いて得られる成形品
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
PL2024367T3 (pl) 2006-05-04 2011-05-31 Chiesi Farm Spa Tetrahydropirolopirymidynodiony i ich zastosowanie jako inhibitory ludzkiej elastazy neutrofilowej
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008030158A1 (en) 2006-09-04 2008-03-13 Astrazeneca Ab Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
BRPI0819258A2 (pt) * 2007-11-06 2017-05-02 Astrazeneca Ab alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
CA2773618A1 (en) 2011-04-07
US8436024B2 (en) 2013-05-07
KR20120099639A (ko) 2012-09-11
US20110082155A1 (en) 2011-04-07
BR112012007322A2 (pt) 2017-06-06
RU2012116877A (ru) 2013-11-10
UY32918A (es) 2011-04-29
AU2010302420A1 (en) 2012-04-19
EP2483244A1 (en) 2012-08-08
WO2011039528A1 (en) 2011-04-07
AU2010302420B2 (en) 2013-07-04
JP2013506649A (ja) 2013-02-28
MX2012003644A (es) 2012-04-30
CN102639505A (zh) 2012-08-15
TW201118078A (en) 2011-06-01

Similar Documents

Publication Publication Date Title
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
CO6680699A2 (es) Derivados de amina para el control de plagas
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
UY29633A1 (es) Derivados de oxindol
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
SE0403171D0 (sv) New compounds
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR087487A1 (es) Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak)
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR067927A1 (es) Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure